Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 9597362, 9 pages
https://doi.org/10.1155/2018/9597362
Research Article

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts

1Syreon Research Institute, Budapest, Hungary
2Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary
3Department of Pharmaceutics and Central Clinical Pharmacy, University of Pécs, Pécs, Hungary
4Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria
5Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
6Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia
7Management Center Innsbruck, Innsbruck, Austria
8Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic
9Kazakh Agency for Health Technology Assessment, Astana, Kazakhstan
10Syreon Research Romania, Tirgu Mures, Romania
11Faculty of Technical and Human Sciences, Sapientia University, Tirgu Mures, Romania
12Center of Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation, Moscow, Russia
13Egis Pharmaceuticals, Budapest, Hungary

Correspondence should be addressed to Andras Inotai

Received 31 August 2017; Accepted 6 December 2017; Published 10 January 2018

Academic Editor: Joao Eurico Fonseca

Copyright © 2018 Andras Inotai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organisation, “Life expectancy, 2015,” http://apps.who.int/gho/data/view.main.SDG2016LEXv?lang=en.
  2. Z. Kaló, L. Annemans, and L. P. Garrison, “Differential pricing of new pharmaceuticals in lower income European countries,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 13, no. 6, pp. 735–741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. P. G. Kanavos and S. Vandoros, “Determinants of branded prescription medicine prices in OECD countries,” Health Economics, Policy and Law, vol. 6, no. 3, pp. 337–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Elek, E. Takács, G. Merész, and Z. Kaló, “Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries,” Health Policy and Planning, vol. 32, no. 3, pp. 349–358, 2017. View at Publisher · View at Google Scholar
  5. A. Inotai, G. Petrova, D. Vitezic, and Z. Kaló, “Benefits of investment into modern medicines in Central-Eastern European countries,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 14, no. 1, pp. 71–79, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. Kaló, K. Landa, T. Doležal, and Z. Vokó, “Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries,” European Journal of Cancer Care, vol. 21, no. 4, pp. 442–449, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Moorkens, C. Jonker-Exler, I. Huys, P. Declerck, S. Simoens, and A. G. Vulto, “Overcoming barriers to the market access of biosimilars in the European union: The case of biosimilar monoclonal antibodies,” Frontiers in Pharmacology, vol. 7, article no. 193, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Rémuzat, A. Kapuśniak, A. Caban et al., “Supply-side and demand-side policies for biosimilars: an overview in 10 European member states,” Journal of Market Access & Health Policy, vol. 5, no. 1, p. 1307315, 2017. View at Publisher · View at Google Scholar
  9. A. Inotai, M. Csanádi, D. Vitezic, and et al., “Policy Practices to Maximise Social Benefit from Biosimilars,” Journal of Bioequivalence & Bioavailability, vol. 9, no. 4, pp. 467–472, 2017. View at Google Scholar
  10. Z. Kaló, Z. Vokó, A. Östör et al., “Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region,” Journal of Market Access & Health Policy, vol. 5, no. 1, article no. 1345580, 2017. View at Publisher · View at Google Scholar
  11. L. P. Garrison, “Pharmacoeconomics and Drug Pricing,” in Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs, R. J. Y. Ho and M. Gibaldi, Eds., John Wiley and Sons, 2nd edition, 2013. View at Google Scholar
  12. E. Choy and I. A. Jacobs, “Biosimilar safety considerations in clinical practice,” Seminars in Oncology, vol. 41, no. 1, pp. S3–S14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Calo-Fernández and J. L. Martínez-Hurtado, “Biosimilars: Company strategies to capture value from the biologics market,” Pharmaceuticals, vol. 5, no. 12, pp. 1393–1408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. E. Emmanouilides, M. I. Karampola, and M. Beredima, “Biosimilars: Hope and concern,” Journal of Oncology Pharmacy Practice, vol. 22, no. 4, pp. 618–624, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Müller, C. Renner, C. Gabay, G. Cassata, A. Lohri, and P. Hasler, “The advent of biosimilars: Challenges and risks,” Swiss Medical Weekly, vol. 144, Article ID w13980, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Braun and A. Kudrin, “Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health,” Biologicals, vol. 44, no. 4, pp. 257–266, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Schellekens, “Biosimilar therapeutics—what do we need to consider?” NDT Plus, vol. 2, supplement 1, pp. i27–i36, 2009. View at Publisher · View at Google Scholar
  18. A. Kudrin, I. Knezevic, J. Joung, and H. N. Kang, “Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval,” Biologicals, vol. 43, no. 1, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Markus, J. Liu, M. Ramchandani, D. Landa, T. Born, and P. Kaur, “Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community,” BioDrugs, vol. 31, no. 3, pp. 175–187, 2017. View at Publisher · View at Google Scholar
  20. V. Strand, A. Balsa, J. Al-Saleh et al., “Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review,” BioDrugs, vol. 31, no. 4, pp. 299–316, 2017. View at Publisher · View at Google Scholar
  21. S. R. Feldman, “Inflammatory diseases: Integrating biosimilars into clinical practice,” Seminars in Arthritis and Rheumatism, vol. 44, no. 6, pp. S16–S21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Jeske, J. M. Walenga, D. Hoppensteadt, and J. Fareed, “Update on the safety and bioequivalence of biosimilars - Focus on enoxaparin,” Journal of Drug, Healthcare and Patient Safety, vol. 5, no. 1, pp. 133–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Kurki, L. van Aerts, E. Wolff-Holz, T. Giezen, V. Skibeli, and M. Weise, “Interchangeability of Biosimilars: A European Perspective,” BioDrugs, vol. 31, no. 2, pp. 83–91, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Inotai, C. P. Prins, M. Csanádi, D. Vitezic, C. Codreanu, and Z. Kaló, “Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars,” Expert Opinion on Biological Therapy, vol. 17, no. 8, pp. 915–926, 2017. View at Publisher · View at Google Scholar
  25. V. Annese, M. Vecchi, F. Bossa et al., “Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease,” Digestive and Liver Disease, vol. 46, no. 11, pp. 963–968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Atzeni, M. Sebastiani, and C. Ricci, “Position paper of Italian rheumatologists on the use of biosimilar drugs,” Clinical and Experimental Rheumatology, vol. 33, no. 1, pp. 1–4, 2014. View at Publisher · View at Google Scholar
  27. G. Barosi, A. Bosi, M. P. Abbracchio et al., “Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation,” Haematologica, vol. 96, no. 7, pp. 937–942, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Gomollón, “Biosimilars: Are they bioequivalent?” Digestive Diseases, vol. 32, pp. 82–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Gulácsi, V. Brodszky, P. Baji, F. Rencz, and M. Péntek, “The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries,” Advances in Therapy, vol. 34, no. 5, pp. 1128–1144, 2017. View at Publisher · View at Google Scholar
  30. C. Rémuzat, J. Dorey, O. Cristeau, D. Ionescu, G. Radière, and M. Toumi, “Key drivers for market penetration of biosimilars in Europe,” Journal of Market Access & Health Policy, vol. 5, no. 1, p. 1272308, 2017. View at Publisher · View at Google Scholar
  31. N. Swartenbroekx, Farfan-Portet, J. Espín, and S. Gerkens, “Incentives for market penetration of biosimilars in Belgium and in five European countries,” Journal de Pharmacie de Belgique, no. 4, pp. 36–46, 2014. View at Google Scholar · View at Scopus
  32. P. Dylst, A. Vulto, and S. Simoens, “Barriers to the uptake of biosimilars and possible solutions: A Belgian case study,” PharmacoEconomics, vol. 32, no. 7, pp. 681–691, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Kawalec, E. Stawowczyk, T. Tesar et al., “Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries,” Frontiers in Pharmacology, vol. 8, 2017. View at Publisher · View at Google Scholar
  34. Z. Kaló, A.-P. Holtorf, R. Alfonso-Cristancho et al., “Need for multicriteria evaluation of generic drug policies,” Value in Health, vol. 18, no. 2, pp. 346–351, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Parkinson, C. Sermet, F. Clement, and et al., “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review,” Pharmacoeconomics, vol. 33, no. 9, pp. 905–924, 2015. View at Google Scholar
  36. F. Rencz, M. Pentek, M. Bortlik et al., “Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe,” World Journal of Gastroenterology, vol. 21, no. 6, p. 1728, 2015. View at Publisher · View at Google Scholar
  37. “Celltrion Remicade biosimilar gathers momentum in EU, 2015,” http://www.pharmatimes.com/news/celltrion_remicade_biosimilar_gathers_momentum_in_eu_971086.
  38. B. Lunddahl, “Pharmacovigilance on biologicals and biosimilars: A Danish perspective,” GaBI Journal, vol. 5, no. 3, pp. 123-124, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Papamichael, T. Van Stappen, V. Jairath et al., “Review article: Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases,” Alimentary Pharmacology & Therapeutics, vol. 42, no. 10, pp. 1158–1169, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. K. McKeage, “A Review of CT-P13: an Infliximab Biosimilar,” BioDrugs, vol. 28, no. 3, pp. 313–321, 2014. View at Publisher · View at Google Scholar
  41. H. C. Ebbers, M. Muenzberg, and H. Schellekens, “The safety of switching between therapeutic proteins,” Expert Opinion on Biological Therapy, vol. 12, no. 11, pp. 1473–1485, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. “Biologics in the Polish health system, 2015,” http://www.infarma.pl/assets/files/innowacje/Biologics_in_the_Polish_health_system.pdf.
  43. A. V. Pinheiro, M. Vithlani, K. Sarnataro, and et al., “Impact of market access factors in the adoption of biosimilar anti-TNFs across Europe. Precision for Value report, 2016,” http://www.precisionforvalue.com/wp-content/uploads/2016/05/Impact-of-Market-Access-Factors-Across-Europe.pdf.
  44. “Pacte d’avenir pour le patient avec l’industrie pharmaceutique, 2015,” http://www.deblock.belgium.be/sites/default/files/articles/20150727%20Pacte%20d’avenir.pdf.
  45. “ANSM report, État des lieux sur les médicaments biosimilaires, 2016,” http://ansm.sante.fr/var/ansm_site/storage/original/application/c35f47c89146b71421a275be7911a250.pdf.
  46. A. Hemmington, N. Dalbeth, P. Jarrett et al., “Medical specialists' attitudes to prescribing biosimilars,” Pharmacoepidemiology and Drug Safety, vol. 26, no. 5, pp. 570–577, 2017. View at Publisher · View at Google Scholar · View at Scopus